Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: Efficacy and safety

Haemophilia

Volumn 22, Issue 2, 2016, Pages 225-231

  Lissitchkov, T ^a   Hampton, K ^b   von Depka, M ^c   Hay, C ^d   Rangarajan, S ^e   Tuddenham, E ^f   Holstein, K ^g   Huth Kuhne A ^h   Pabinger, I ⁱ   Knaub, S ^j   Bichler, J ^j   Oldenburg, J ^k  

^a Specialised Hospital for Active Treatment Joan Pavel   (Bulgaria)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c Werlhof Institute GmbH   (Germany)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h Kurpfalzkrankenhaus Hosp/Hemophilia   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j Octapharma AG   (Switzerland)

^k UNIVERSITY OF BONN   (Germany)

more..

Author keywords

Factor VIII inhibitors; Haemophilia A; Human cell line factor VIII; Nuwiq; Prophylaxis; Recombinant factor VIII

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOPHILIA A; HUMAN; IN VIVO STUDY; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; MAJOR SURGERY; MALE; MINOR SURGERY; OPERATIVE BLOOD LOSS; PARESTHESIA; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA;

EID: 84960454393     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12793     Document Type: Article

References (40)

1. Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11: 178-82.
2. Coppola A, Di CM, Di Minno MN et al. Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med 2010; 1: 183-95.
3. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8.
4. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
5. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 2004; 10: 147-57.
6. Astermark J. Prevention and prediction of inhibitor risk. Haemophilia 2012; 18(Suppl. 4): 38-42.
7. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
8. Brown TM, Lee WC, Joshi AV et al. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia 2009; 15: 911-7.
9. Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
10. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
11. Gringeri A, Mantovani LG, Scalone L et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
12. Gouw SC, van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
13. Xi M, Makris M, Marcucci M et al. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11: 1655-62.
14. Hay CR, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
15. Lenting PJ, Christophe OD, Gueguen P. The disappearing act of factor VIII. Haemophilia 2010; 16: 6-15.
16. Kosloski MP, Miclea RD, Balu-Iyer SV. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J 2009; 11: 424-31.
17. Leyte A, Van Schijndel HB, Niehrs C et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266: 740-6.
18. Kannicht C, Ramstrom M, Kohla G et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2013; 131: 78-88.
19. Brooks SA. Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system. Mol Biotechnol 2004; 28: 241-55.
20. Casademunt E, Martinelle K, Jernberg M et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol 2012; 89: 165-76.
21. Sandberg H, Kannicht C, Stenlund P et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 2012; 130: 808-17.
22. Kobayashi T, Ezzelarab M. Glycobiology relating to xenotransplantation. Curr Opin Organ Transplant 2006; 11: 1541-59.
23. Diaz SL, Padler-Karavani V, Ghaderi D et al. Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PLoS ONE 2009; 4: e4241.
24. Macher BA, Galili U. The Galα1, 3Galβ1, 4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 2008; 1780: 75-88.
25. Hokke CH, Bergwerff AA, van Dedem GW et al. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett 1990; 275: 9-14.
26. Hironaka T, Furukawa K, Esmon PC et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992; 267: 8012-20.
27. European Medicines Agency. Guideline on the investigation of human plasma-derived factor VIII and IX products. London, UK, 2011. Report No.: EMA/CHMP/BPWP/144533/2009.
28. Feldman BM, Funk SM, Bergstrom BM et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63: 223-30.
29. Hilliard P, Funk S, Zourikian N et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12: 518-25.
30. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
31. Barrowcliffe TW, Raut S, Sands D et al. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 247-56.
32. Collins P, Faradji A, Morfini M et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
33. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
34. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27. Corrigendum: J Thromb Haemost 2013; 12: 119-22.
35. Klamroth R, Lissitchkov T, Rusen L et al. Personalized prophylaxis with human-cl rhFVIII in hemophilia A patients. J Thromb Haemost 2015; 13(Suppl. 2): 850.
36. Recht M, Nemes L, Matysiak M et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 869-80.
37. ™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19: 691-7.
38. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
39. Tarantino MD, Collins PW, Hay CR et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
40. Valentino LA, Negrier C, Kohla G et al. The first recombinant FVIII produced in human cells - an update on its clinical development programme. Haemophilia 2014; 20(Suppl. 1): 1-9.